Inhibition of thioredoxin-1 enhances the toxicity of glycolysis inhibitor 2-deoxyglucose by downregulating SLC1A5 expression in colorectal cancer cells

Pyrolyzed deketene curcumin controls regulatory T cell generation and gastric cancer metabolism cooperate with 2-deoxy-d-glucose

(2023) Takashi MaruYama et al.   Frontiers in Immunology

Illuminating and Radiosensitizing Tumors with 2DG-Bound Gold-Based Nanomedicine for Targeted CT Imaging and Therapy

(2023) Maharajan Sivasubramanian et al.   Nanomaterials

Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications

(2022) Xinyang Zhong et al.   Journal of Hematology & Oncology

Tumor glycolysis, an essential sweet tooth of tumor cells

(2022) Sumana Paul et al.   SEMINARS IN CANCER BIOLOGY

Multifaceted entrancing role of glucose and its analogue, 2-deoxy-D-glucose in cancer cell proliferation, inflammation, and virus infection

(2022) Sananda Dey et al.   BIOMEDICINE & PHARMACOTHERAPY

Ezrin accelerates breast cancer liver metastasis through promoting furin-like convertase-mediated cleavage of Notch1

(2022) Miaojuan Chen et al.   CELLULAR ONCOLOGY

Co-delivery of 2-Deoxyglucose and a glutamine metabolism inhibitor V9302 via a prodrug micellar formulation for synergistic targeting of metabolism in cancer

(2020) Zhangyi Luo et al.   Acta Biomaterialia

Thioredoxin-1 distinctly promotes NF-κB target DNA binding and NLRP3 inflammasome activation independently of Txnip

(2020) Jonathan Muri et al.   eLife

Cellular toxicity of the metabolic inhibitor 2-deoxyglucose and associated resistance mechanisms

(2020) Clotilde Laussel et al.   BIOCHEMICAL PHARMACOLOGY

Cancer statistics, 2019

(2019) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Increased Thioredoxin-1 Expression Promotes Cancer Progression and Predicts Poor Prognosis in Patients with Gastric Cancer

(2019) Wenjing Shang et al.   Oxidative Medicine and Cellular Longevity

Targeting the ROS/PI3K/AKT/HIF‐1α/HK2 axis of breast cancer cells: Combined administration of Polydatin and 2‐Deoxy‐d‐glucose

(2019) Tao Zhang et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Dietary 2-deoxy-D-glucose impairs tumour growth and metastasis by inhibiting angiogenesis

(2019) Saurabh Singh et al.   EUROPEAN JOURNAL OF CANCER

Radioresistant Cervical Cancers Are Sensitive to Inhibition of Glycolysis and Redox Metabolism

(2018) Ramachandran Rashmi et al.   CANCER RESEARCH

Interplay between Trx-1 and S100P promotes colorectal cancer cell epithelial-mesenchymal transition by up-regulating S100A4 through AKT activation

(2018) Zhigui Zuo et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Repurposing Auranofin, Ebselen, and PX-12 as Antimicrobial Agents Targeting the Thioredoxin System

(2018) Holly C. May et al.   Frontiers in Microbiology

ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis

(2016) Haiquan Lu et al.   CANCER LETTERS

TORquing metabolic reprogramming in cancer cells

(2016) Raju Pusapati et al.   CELL CYCLE

2-Deoxyglucose Reverses the Promoting Effect of Insulin on Colorectal Cancer Cells In Vitro

(2016) Dongsheng Zhang et al.   PLoS One

Inhibition of glucose metabolism prevents glycosylation of the glutamine transporter ASCT2 and promotes compensatory LAT1 upregulation in leukemia cells

(2016) Florence Polet et al.   Oncotarget

N-linked Glycosylation of human SLC1A5 (ASCT2) transporter is critical for trafficking to membrane

(2015) Lara Console et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Regulation of Glutamine Carrier Proteins by RNF5 Determines Breast Cancer Response to ER Stress-Inducing Chemotherapies

(2015) Young Joo Jeon et al.   CANCER CELL

ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer

(2015) M van Geldermalsen et al.   ONCOGENE

Defining the Role of Tyrosine Kinase Inhibitors in Early Stage Non-Small Cell Lung Cancer

(2015) Sofia Lampaki et al.   Journal of Cancer

Combined inhibition of glycolysis, the pentose cycle, and thioredoxin metabolism selectively increases cytotoxicity and oxidative stress in human breast and prostate cancer

(2015) Ling Li et al.   Redox Biology

Thioredoxin-1 inhibitor, 1-methylpropyl 2-imidazolyl disulfide, inhibits the growth, migration and invasion of colorectal cancer cell lines

(2014) FULE WANG et al.   ONCOLOGY REPORTS

Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia

(2013) L. Willems et al.   BLOOD

Differential sensitivities of glioblastoma cell lines towards metabolic and signaling pathway inhibitions

(2013) Colin R. Kennedy et al.   CANCER LETTERS

Glutamine and cancer: cell biology, physiology, and clinical opportunities

(2013) Christopher T. Hensley et al.   JOURNAL OF CLINICAL INVESTIGATION

Tumor glycolysis as a target for cancer therapy: progress and prospects

(2013) Shanmugasundaram Ganapathy-Kanniappan et al.   Molecular Cancer

Modulation of oxidative stress as an anticancer strategy

(2013) Chiara Gorrini et al.   NATURE REVIEWS DRUG DISCOVERY

SLC1A5 Mediates Glutamine Transport Required for Lung Cancer Cell Growth and Survival

(2012) M. Hassanein et al.   CLINICAL CANCER RESEARCH

Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions

(2012) Isabelle Soerjomataram et al.   LANCET

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Thioredoxin stimulates MMP-9 expression, de-regulates the MMP-9/TIMP-1 equilibrium and promotes MMP-9 dependent invasion in human MDA-MB-231 breast cancer cells

(2011) Antonietta R. Farina et al.   FEBS LETTERS

Comparative Metabolic Flux Profiling of Melanoma Cell Lines

(2011) David A. Scott et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Glutamine: pleiotropic roles in tumor growth and stress resistance

(2011) Naval P. Shanware et al.   JOURNAL OF MOLECULAR MEDICINE-JMM